Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin 100 mg;   Drug: Placebo/sitagliptin 2x50 mg;   Drug: Canagliflozin 300 mg
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010

Condition:   Acute Gout
Interventions:   Drug: ACZ885;   Drug: Triamcinolone acetonide
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting - verified March 2010

Condition:   Asthma
Interventions:   Drug: Indacaterol dose;   Drug: Placebo;   Drug: Salmeterol
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: Placebo;   Drug: Tiotropium
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Pfizer
Recruiting - verified March 2010

Condition:   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: Indacaterol;   Drug: Placebo
Sponsor:   Novartis
Recruiting - verified February 2010

Conditions:   Breast Cancer;   Diagnostic Imaging
Intervention:   Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsor:   Bayer
Not yet recruiting - verified February 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: NN1250;   Drug: sitagliptin
Sponsor:   Novo Nordisk
Recruiting - verified March 2010

Condition:   Pancreatic Cancer
Interventions:   Drug: capecitabine;   Drug: erlotinib hydrochloride;   Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: bevacizumab;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Other: placebo
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Endometrial Cancer
Interventions:   Drug: MEK inhibitor AZD6244;   Other: laboratory biomarker analysis
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Active Rheumatoid Arthritis
Intervention:   Drug: SBI-087
Sponsor:   Wyeth
Recruiting - verified February 2010

Condition:   Rheumatoid Arthritis
Interventions:   Drug: tocilizumab [RoActemra];   Drug: tociliumab;   Drug: methotrexate
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
Recruiting - verified March 2010

Condition:   Liver Cancer
Interventions:   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: liver transplantation;   Procedure: therapeutic conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Neurotoxicity
Interventions:   Drug: temozolomide;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Rheumatoid Arthritis
Interventions:   Biological: LY2439821;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2010

Condition:   Vertebral Compression Fractures
Intervention:   Device: OsseoFix Spinal Fracture Reduction System
Sponsor:   Alphatec Spine, Inc.
Recruiting - verified March 2010

Condition:   Arthritis, Rheumatoid
Interventions:   Drug: CP-690,550;   Drug: CP-690,550;   Drug: Placebo;   Drug: CP-690,550;   Drug: Placebo;   Drug: CP-690,550
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Metformin XR;   Drug: Metformin XR
Sponsors:   AstraZeneca;   Bristol-Myers Squibb
Recruiting - verified February 2010

Condition:   Leukemia
Interventions:   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Seasonal Influenza;   Cough;   Sore Throat;   Nasal Congestion;   Myalgia;   Headache;   Fatigue
Interventions:   Drug: Peramivir;   Drug: Peramivir
Sponsors:   BioCryst Pharmaceuticals;   Department of Health and Human Services
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Drug: carboplatin;   Drug: ifosfamide;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Rheumatoid Arthritis
Interventions:   Drug: AMG 827 70 mg;   Drug: AMG 827 140 mg;   Drug: AMG 827 210 mg;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Bladder Cancer;   Prostate Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: placebo administration
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Endometrial Cancer
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Asthma
Interventions:   Drug: QMF149 Twisthaler®;   Drug: Mometasone Twisthaler®
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Condition:   Rheumatoid Arthritis
Interventions:   Drug: PF-04171327 10 mg;   Other: Prednisone Placebo;   Drug: PF-04171327 25 mg;   Other: Prednisone Placebo;   Drug: Prednisone 5 mg;   Other: Placebo for PF-04171327;   Other: Placebo;   Other: Placebo for PF-04171327
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin;   Drug: leuprolide acetate;   Drug: triptorelin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Overactive Bladder
Interventions:   Drug: Fesoterodine;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Contrast Induced Nephropathy
Intervention:   Drug: sodium bicarbonate
Sponsor:   MD Scientific
Recruiting - verified February 2010

Conditions:   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Precancerous Condition
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chordoma;   Desmoid Tumor;   Sarcoma
Interventions:   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Advanced Breast Cancer;   Breast Cancer
Interventions:   Drug: Neratinib + Paclitaxel;   Drug: Trastuzumab + Paclitaxel
Sponsor:   Wyeth
Recruiting - verified March 2010

Condition:   Alzheimer Disease
Interventions:   Drug: bapineuzumab;   Drug: placebo
Sponsor:   Wyeth
Recruiting - verified February 2010

Condition:   Neuroblastoma
Interventions:   Genetic: loss of heterozygosity analysis;   Other: cytology specimen collection procedure;   Procedure: biopsy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Herpes Zoster;   Shingles
Interventions:   Drug: valacyclovir;   Drug: FV-100;   Drug: FV-100;   Drug: Valacyclovir placebo;   Drug: FV-100 placebo
Sponsor:   Inhibitex
Recruiting - verified February 2010

Condition:   Sarcoma
Interventions:   Other: biologic sample preservation procedure;   Other: medical chart review
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Genetic: microarray analysis;   Other: laboratory biomarker analysis
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Other: biologic sample preservation procedure;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Head and Neck Cancer
Interventions:   Other: biologic sample preservation procedure;   Procedure: biopsy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Neoplasm of Uncertain Malignant Potential;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Other: cytology specimen collection procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Leukemia;   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Nonneoplastic Condition
Interventions:   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Procedure: computed tomography;   Procedure: magnetic resonance imaging
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Genetic: DNA analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   End Stage Renal Disease
Intervention:   Procedure: Graft placement surgery plus Trinam therapy
Sponsor:   Ark Therapeutics Ltd
Recruiting - verified December 2009

Condition:   Rheumatoid Arthritis
Interventions:   Drug: tocilizumab [RoActemra];   Drug: tocilizumab [RoActemra];   Drug: Nonbiologic DMARDs of investigator's choice
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Coronary Artery Chronic Total Occlusion
Intervention:   Device: Recanalization of a coronary chronic total occlusion
Sponsor:   BridgePoint Medical
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: neratinib;   Other: placebo
Sponsor:   Wyeth
Recruiting - verified March 2010

Condition:   Depression
Interventions:   Other: Placebo;   Drug: orvepitant
Sponsor:   GlaxoSmithKline
Recruiting - verified February 2010

Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Procedure: assessment of therapy complications
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma
Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Coronary Artery Bypass;   Myocardial Infarction;   Ventricular Dysfunction, Left;   Stroke;   Cardiopulmonary Bypass
Interventions:   Drug: Acadesine;   Drug: Normal Saline
Sponsor:   Schering-Plough
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Musculoskeletal Complications;   Pain;   Prostate Cancer;   Urinary Complications
Intervention:   Drug: zoledronic acid
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Arthritis, Rheumatoid
Interventions:   Drug: CP-690,550;   Drug: CP-690,550;   Drug: Placebo;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Anemia;   Leukemia;   Myelodysplastic Syndromes
Interventions:   Biological: epoetin alfa;   Drug: lenalidomide
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cytarabine;   Drug: idarubicin;   Drug: pravastatin
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Adrenocortical Carcinoma;   Kidney Cancer;   Liver Cancer;   Neuroblastoma;   Retinoblastoma;   Sarcoma
Interventions:   Biological: cixutumumab;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Arthritis;   Osteoarthritis
Interventions:   Biological: tanezumab 10 mg;   Biological: tanezumab 5 mg;   Drug: naproxen;   Other: placebo
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Lung Cancer
Interventions:   Biological: aflibercept;   Drug: topotecan hydrochloride
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine;   Drug: vincristine sulfate;   Radiation: fludeoxyglucose F 18
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Osteoarthritis
Interventions:   Biological: tanezumab;   Biological: tanezumab;   Biological: tanezumab
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Osteoarthritis;   Arthritis
Interventions:   Drug: NSAID;   Biological: tanezumab;   Biological: tanezumab;   Biological: tanezumab;   Drug: NSAID;   Biological: tanezumab;   Drug: NSAID
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Rheumatoid Arthritis
Interventions:   Drug: infliximab;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: ocrelizumab;   Drug: sham
Sponsor:   Genentech
Recruiting - verified February 2010

Conditions:   Endometrial Cancer;   Fatigue;   Neurotoxicity
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Radiation: brachytherapy;   Radiation: intensity-modulated radiation therapy;   Radiation: radiation therapy
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cervical Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: paclitaxel;   Drug: topotecan hydrochloride
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dasatinib;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: prednisone;   Drug: sirolimus;   Drug: tacrolimus;   Drug: vincristine sulfate;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Other: active surveillance
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: ixabepilone;   Drug: paclitaxel;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Diabetic Neuropathy, Painful
Interventions:   Drug: Placebo;   Drug: pregabalin;   Drug: LY545694;   Drug: LY545694;   Drug: LY545694
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2010

Condition:   Bladder Cancer
Interventions:   Drug: cisplatin;   Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Advanced Breast Cancer;   Breast Cancer
Interventions:   Drug: Neratinib;   Drug: Lapatinib plus Capecitabine
Sponsor:   Wyeth
Recruiting - verified February 2010

Conditions:   Breast Cancer;   Chemotherapeutic Agent Toxicity;   Fatigue;   Neuropathy;   Neurotoxicity
Interventions:   Dietary Supplement: acetyl-L-carnitine hydrochloride;   Other: placebo
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Deep Vein Thrombosis;   Venous Thrombosis;   Postphlebitic Syndrome;   Venous Thromboembolism;   Post Thrombotic Syndrome
Intervention:   Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors:   Washington University School of Medicine;   McMaster University;   Ontario Clinical Oncology Group (OCOG);   National Heart, Lung, and Blood Institute (NHLBI);   Bacchus Vascular;   BSN Medical Inc;   Genentech;   MEDRAD Interventional/Possis;   Mid America Heart Institute;   Society of Interventional Radiology Foundation;   VasCore at Massachusetts General Hospital
Recruiting - verified February 2010

Condition:   Carcinoma, Non-Small Cell Lung
Interventions:   Drug: axitinib;   Drug: axitinib;   Drug: chemotherapy;   Drug: axitinib;   Drug: chemotherapy
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Biological: tositumomab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Radiation: iodine I 131 tositumomab
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions:   Biological: panitumumab;   Drug: cisplatin;   Drug: docetaxel;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsors:   American College of Surgeons;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Arthritis;   Osteoarthritis;   Osteoarthritis, Hip
Interventions:   Biological: tanezumab;   Biological: tanezumab;   Biological: tanezumab;   Biological: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Diabetes Mellitus
Interventions:   Drug: Exubera;   Other: Randomized diabetes therapy
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY2189265;   Drug: Sitagliptin 100mg, 24 months;   Drug: Placebo solution;   Drug: Placebo tablet, 6 months;   Drug: Placebo tablet, 24 months;   Drug: Sitagliptin 100 mg, 18 months
Sponsors:   Eli Lilly and Company;   United BioSource Corporation;   Tessella Inc.;   Berry Consultants
Recruiting - verified February 2010

Condition:   Fibromyalgia
Intervention:   Drug: Treatment for Fibromyalgia
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2010

Condition:   Rheumatoid Arthritis
Interventions:   Drug: tocilizumab [RoActemra];   Drug: Standard anti-rheumatic treatment
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dasatinib;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Head and Neck Cancer
Interventions:   Drug: cisplatin;   Drug: vandetanib;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: cixutumumab;   Drug: capecitabine;   Drug: lapatinib ditosylate
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: bortezomib;   Drug: cytarabine;   Drug: etoposide phosphate;   Drug: idarubicin
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Human Immunodeficiency Virus
Interventions:   Drug: Maraviroc along with an optimized background antiretroviral drug regimen;   Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Drug: carboplatin;   Drug: erlotinib hydrochloride;   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: azacitidine;   Drug: gemtuzumab ozogamicin
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Esophageal Cancer
Interventions:   Biological: cetuximab;   Drug: cisplatin;   Drug: paclitaxel;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
Recruiting - verified March 2010

Condition:   Pancreatic Cancer
Interventions:   Biological: cixutumumab;   Drug: erlotinib hydrochloride;   Drug: gemcitabine hydrochloride
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: rituximab;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: lenalidomide
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   NCIC Clinical Trials Group;   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Infrarenal Abdominal Aortic Aneurysm
Intervention:   Device: Anaconda Stent Graft System
Sponsors:   Terumo CVS;   Vascutek Ltd., Scotland
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: letrozole;   Drug: tamoxifen citrate;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Head and Neck Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: fluorouracil
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: flutamide;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Neuroendocrine Carcinoma
Interventions:   Biological: bevacizumab;   Biological: recombinant interferon alfa-2b;   Drug: octreotide acetate
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Cognitive/Functional Effects;   Metastatic Cancer;   Neurotoxicity;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: memantine hydrochloride;   Other: placebo;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: docetaxel;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Osteoarthritis
Interventions:   Drug: SD-6010;   Drug: SD-6010;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2010

Conditions:   Head and Neck Cancer;   Squamous Cell Cancer
Intervention:   Drug: Zalutumumab
Sponsor:   Genmab
Recruiting - verified February 2010

Condition:   Aspergillosis
Interventions:   Drug: voriconazole;   Drug: anidulafungin;   Drug: voriconazole
Sponsors:   Pfizer;   Mycoses Study Group
Recruiting - verified February 2010

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: docetaxel;   Drug: flutamide;   Drug: goserelin;   Drug: leuprolide acetate;   Procedure: adjuvant therapy;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Epilepsy
Interventions:   Drug: lacosamide;   Drug: lacosamide
Sponsor:   UCB, Inc.
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Procedure: thoracoscopic surgery;   Procedure: videothoracoscopy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   American College of Surgeons;   Southwest Oncology Group
Recruiting - verified March 2010

Conditions:   Candidiasis;   Candida
Intervention:   Drug: anidulafungin
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Cancer and Leukemia Group B;   Eastern Cooperative Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: topotecan hydrochloride
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin;   Other: clinical observation
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: Trastuzumab;   Drug: Lapatinib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Conditions:   Neurotoxicity;   Pain;   Peripheral Neuropathy;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: duloxetine hydrochloride;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Invasive Breast Cancer
Interventions:   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: paclitaxel;   Drug: trastuzumab;   Drug: lapatinib
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   GlaxoSmithKline
Recruiting - verified February 2010

Condition:   Leukemia
Interventions:   Genetic: DNA ploidy analysis;   Genetic: chromosomal translocation analysis;   Genetic: fluorescence in situ hybridization;   Genetic: polymorphism analysis;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: biopsy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Heart Decompensation
Interventions:   Drug: Placebo;   Drug: Nesiritide
Sponsor:   Scios, Inc.
Recruiting - verified February 2010

Condition:   Lung Cancer
Interventions:   Genetic: chromogenic in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: fluorescent antibody technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Other: study of socioeconomic and demographic variables;   Procedure: study of high risk factors
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: erlotinib hydrochloride
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Bladder Cancer
Interventions:   Drug: gemcitabine hydrochloride;   Other: placebo
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: erlotinib hydrochloride
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: cyclophosphamide;   Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: placebo
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: dasatinib;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Other: immunologic technique;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study;   Procedure: biopsy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Arthritis, Rheumatoid
Interventions:   Drug: CP-690,550;   Drug: CP-690,550
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Metastatic Cancer
Intervention:   Drug: dasatinib
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Procedure: conventional surgery
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: nelarabine;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Esophageal Cancer
Interventions:   Biological: cetuximab;   Drug: cisplatin;   Drug: epirubicin hydrochloride;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
Recruiting - verified June 2009

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: bevacizumab;   Drug: sorafenib tosylate;   Drug: temsirolimus
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: gemtuzumab ozogamicin;   Drug: mitoxantrone hydrochloride
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: clofarabine;   Drug: cytarabine;   Drug: methotrexate;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: thioguanine
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Alzheimer's Disease
Interventions:   Drug: raloxifene;   Drug: Placebo
Sponsors:   Stanford University;   National Institute on Aging (NIA);   Indiana University;   Kaiser Permanente;   Southern Illinois University
Recruiting - verified February 2010

Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Pain;   Prostate Cancer
Interventions:   Dietary Supplement: calcium carbonate;   Dietary Supplement: calcium citrate;   Dietary Supplement: calcium glucarate;   Dietary Supplement: vitamin D;   Drug: calcium gluconate;   Drug: zoledronic acid;   Radiation: samarium Sm 153 lexidronam pentasodium;   Radiation: strontium chloride Sr 89
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Heart Failure;   Anemia;   Cardiovascular Disease;   Ventricular Dysfunction;   Congestive Heart Failure
Interventions:   Drug: Darbepoetin alfa;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Intervention:   Drug: lenalidomide
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Arthritis, Rheumatoid;   Osteoarthritis
Interventions:   Drug: celecoxib;   Drug: Ibuprofen;   Drug: Naproxen
Sponsors:   Pfizer;   The Cleveland Clinic
Recruiting - verified February 2010

Conditions:   Childhood Malignant Fibrous Histiocytoma of Bone;   Sarcoma
Interventions:   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Other: clinical observation;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Retinoblastoma
Interventions:   Drug: carboplatin;   Drug: etoposide;   Drug: vincristine sulfate;   Other: clinical observation
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Drug: sorafenib tosylate;   Drug: sunitinib malate;   Other: placebo
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Southwest Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium;   Drug: vinorelbine ditartrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group
Recruiting - verified March 2010

Condition:   Anal Cancer
Interventions:   Biological: cetuximab;   Drug: cisplatin;   Drug: fluorouracil;   Radiation: radiation therapy
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: azacitidine;   Drug: entinostat
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: chemotherapy;   Drug: exemestane;   Drug: letrozole;   Drug: tamoxifen citrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   American College of Surgeons;   North Central Cancer Treatment Group;   NCIC Clinical Trials Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: antiandrogen therapy;   Drug: docetaxel
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Adrenocortical Carcinoma
Interventions:   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: mitotane;   Procedure: conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Head and Neck Cancer;   Radiation Toxicity
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Drug: fluorouracil;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Bladder Cancer
Interventions:   Biological: trastuzumab;   Drug: paclitaxel;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: clinical observation
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: PEG-interferon alfa-2b;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: methotrexate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University College London Hospitals
Recruiting - verified March 2010

Conditions:   Metastatic Cancer;   Prostate Cancer
Interventions:   Drug: atrasentan hydrochloride;   Drug: docetaxel;   Drug: prednisone;   Other: placebo
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: filgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Drug: cisplatin;   Drug: etoposide;   Drug: gemcitabine hydrochloride;   Drug: methylprednisolone
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: paclitaxel;   Drug: paclitaxel poliglumex;   Other: clinical observation
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Drug: CHOP regimen;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Intervention:   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: epratuzumab;   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Chronic Myeloproliferative Disorders
Intervention:   Drug: decitabine
Sponsors:   University of Chicago;   National Cancer Institute (NCI)
Recruiting - verified June 2007

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Pneumonia, Staphylococcal
Interventions:   Drug: linezolid;   Drug: vancomycin
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: lomustine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: filgrastim;   Biological: pegfilgrastim;   Biological: trastuzumab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Menopausal Symptoms;   Sexual Dysfunction and Infertility
Interventions:   Drug: cyclophosphamide;   Drug: goserelin
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Eastern Cooperative Oncology Group;   International Breast Cancer Study Group
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Radiation: iodine I 125;   Radiation: palladium Pd 103;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Drug: capecitabine;   Drug: fluorouracil;   Drug: oxaliplatin;   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified March 2010

Conditions:   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Ovarian Cancer
Interventions:   Biological: bleomycin sulfate;   Drug: cisplatin;   Drug: etoposide;   Procedure: conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Biological: aldesleukin;   Biological: monoclonal antibody Ch14.18;   Biological: sargramostim;   Drug: isotretinoin
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: letrozole;   Other: placebo
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   International Breast Cancer Study Group;   Eastern Cooperative Oncology Group;   Southwest Oncology Group;   Cancer and Leukemia Group B;   European Organization for Research and Treatment of Cancer
Recruiting - verified June 2009